An Open Label, Proof-of-Principle, Pilot Study to Evaluate Pimavanserin for the Treatment of Motor and Behavioral Symptoms of Tourette Syndrome
Latest Information Update: 29 Oct 2021
At a glance
- Drugs Pimavanserin (Primary)
- Indications Gilles de la Tourette's syndrome; Tic disorders
- Focus Therapeutic Use
- 22 Sep 2021 Results presented at the 25th International Congress of Parkinson's Disease and Movement Disorders
- 16 Mar 2021 New trial record